<code id='0AB142396D'></code><style id='0AB142396D'></style>
    • <acronym id='0AB142396D'></acronym>
      <center id='0AB142396D'><center id='0AB142396D'><tfoot id='0AB142396D'></tfoot></center><abbr id='0AB142396D'><dir id='0AB142396D'><tfoot id='0AB142396D'></tfoot><noframes id='0AB142396D'>

    • <optgroup id='0AB142396D'><strike id='0AB142396D'><sup id='0AB142396D'></sup></strike><code id='0AB142396D'></code></optgroup>
        1. <b id='0AB142396D'><label id='0AB142396D'><select id='0AB142396D'><dt id='0AB142396D'><span id='0AB142396D'></span></dt></select></label></b><u id='0AB142396D'></u>
          <i id='0AB142396D'><strike id='0AB142396D'><tt id='0AB142396D'><pre id='0AB142396D'></pre></tt></strike></i>

          Home / fashion / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:53818
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In